Horizon crosses the Atlantic to acquire Raptor for $800m
Irish drugs producer Horizon Pharma has entered into a definitive agreement with Raptor Pharmaceuticals in which Horizon will buy the US biopharmaceutical company for $800 million.
The transaction, which is expected to close in the fourth quarter of 2016, will allow Horizon to add Procysbi (cysteamine bitartrate),a treatment forpatients with kidney cystinosis, to its portfolio. The drug has patent protection until 2034.
Horizon will also add Quinsair (levofloxacin), a treatment for chronic pulmonary infections.
Timothy Walbert, president of Horizon, said: “The proposed acquisition of Raptor furthers our commitment to helping people with rare diseases and is a significant step in advancing our strategy to expand our rare disease business.”
He added: “Along with the potential for accelerated revenue growth, the addition of Raptor strengthens our US orphan business and provides a platform to expand our orphan business in Europe and other key international markets.”
Julie Anne Smith, president of Raptor, said: “On behalf of the board and management team, I extend our deepest gratitude to everyone at Raptor for their unrelenting commitment to advancing the development of our medicines and their tireless work with the patients we serve.”
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk